Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing

Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing

<b> </b>Immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and anti–programmed cell death-ligand 1 (PD-L1)) are approved as first- and second-line treatments for metastatic UC. PD-L1 expression levels in UC tumors help clinicians determine which patients are more likely to...

Full description

Bibliographic Details
Main Authors: Antonio Lopez-Beltran, Fernando López-Rios, Rodolfo Montironi, Sophie Wildsmith, Markus Eckstein
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
assays
best practice
biomarkers
PD-L1
urothelial carcinoma
Online Access:https://www.mdpi.com/2072-6694/13/6/1424

Internet

https://www.mdpi.com/2072-6694/13/6/1424

Similar Items